NurExone Biologics has been named a finalist in Falling Walls Venture 2025, a global platform that showcases the world’s most promising science-based start-ups. With plans to move into clinical trials next year with an exosome therapy for spinal cord injuries, Diana Turner caught up Dr Lior Shaltiel, CEO and Director. Read More
NervGen Pharma’s lead drug candidate, NVG-291, is being evaluated in an ongoing Phase Ib/IIa clinical trial in partnership with Shirley Ryan AbilityLab for patients with spinal cord injury (SCI). Unlike traditional approaches that manage symptoms, NVG-291 empowers the nervous system to repair itself. DDW’s Megan Thomas speaks with President and… Read More
Scientists investigating potential drugs to improve recovery from spinal cord injury have uncovered a promising route to new treatments. Researchers tested more than 1000 potential drugs and identified that an existing one – cimetidine – improved spinal repair in zebrafish. The drug also helped… Read More
Terebellum and NeurosolvTherapeutics will partner to launch Perineline, a new patented two-part therapy for spinal cord injuries. The drug has attained EMA Orphan Designation and it is hoped that it will revolutionise the therapeutic treatment and resulting end patient outcomes from spinal cord injuries. Terebellum will contribute strategic guidance in… Read More
A group of latent stem cells could be the key to developing new therapeutic approaches to treat brain and spinal cord injuries, research shows. Scientists at the Francis Crick Institute identified a group of latent stem cells in mice which respond to injury in the central nervous system. If the… Read More
An existing drug could help reduce spinal cord injury damage, scientists at the University of Birmingham have discovered. A team of scientists from the University of Birmingham found that an enzyme inhibitor developed by AstraZeneca can significantly reduce ‘secondary damage’ caused by the body’s response to spinal… Read More
